Rafael Esteban Mur

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2011 · 46 citations

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +11

Hepatitis B Vaccination

J Genescá Ferrer, Rafael Esteban Mur · SpringerReference · 2012 · 33 citations

10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2012 · 24 citations

Pharmacy, Infectious Diseases, Hepatitis Pharmacotherapy +13

Number of people treated for hepatitis C virus infection in 2014-2023 and applicable lessons for new HBV and HDV therapies

Homie Razavi, Imam Waked, Huma Qureshi et al. · Journal of Hepatology · 2025 · 18 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Hepatitis A vaccination policy in Catalonia (Spain)

L. Salleras Sanmartí, María Buti Ferret, Emanuel Alcala et al. · Vacunas · 2000 · 10 citations

Public Affairs, Health Policy, Infectious Diseases +12